Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884135 | 0.83 | ALDH1A1 (0.34) | KDM4EKMT2AMEN1HPGDSMN1; SMN2 | |
| SCHEMBL1892476 | 0.83 | ALDH1A1 (0.34) | KDM4EL3MBTL1HPGD | |
| SCHEMBL1892479 | 0.81 | LMNA (0.36) | CHRM2CHRM4CHRM1CHRM3KDM4E | |
| SCHEMBL7404275 | 0.80 | MAP3K14 (0.33) | KMT2ATDP1MEN1APEX1L3MBTL1 | |
| SCHEMBL4440353 | 0.79 | TP53 (0.40) | TP53HTTSMN1; SMN2POLB | |
| SCHEMBL7404277 | 0.77 | MAP3K14 (0.33) | KDM4EHSD17B10KMT2ATDP1MEN1 | |
| SCHEMBL20595274 | 0.77 | TP53 (0.38) | TP53SMN1; SMN2POLB | |
| SCHEMBL7264550 | 0.74 | MAP3K14 (0.40) | KMT2ATDP1MEN1APEX1L3MBTL1 | |
| SCHEMBL3949247 | 0.74 | MAP3K14 (0.40) | KDM4EKMT2ATDP1MEN1APEX1 | |
| SCHEMBL638696 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-07-21 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| EP-2019837-B1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-03-23 | — | — | EP | disclosed |
| EP-2019837-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007140117-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | CHRM2 4077/4885CHRM4 3962/4885CHRM1 4088/4885 |
| US-20110177055-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | CHRM2 4130/4885CHRM4 4018/4885CHRM1 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.